Help for you
and your family
Research for
the cure
Surviving
Lymphoma
Who we are You can help
lymphoma specialist Kai Fu, MD, phd

Kai Fu, M.D. Ph.D.
___________

Professor of Medicine, University of Nebraska Medical Center

Director of Hematopathology Fellowship

Co-Director, Armitage Center for Hematological Malignancies Research

Director, International Relations Office, Buffett Cancer Center


I am really honored and delighted to receive this award from the Foundation. I appreciate the recognition and support from LFA. I hope my research in pathogenesis and pathobiology of lymphoma will ultimately lead to the cure and prevention of the disease. "I am a physician, teacher, and researcher. My research involves several aspects of the hematopathology of lymphomas. I am working on the pathogenesis of lymphoma with particular attention to the gene expression profiles of B-cell nonhodgkin lymphomas and Burkitts lymphoma. I hope to one day be able to identify genes that predict the biologic behavior of different subtypes of lymphoma.

"The resistance of mantle cell lymphoma to current chemotherapy regimens indicates that new therapeutic approaches are needed. Here at the Nebraska Medical Center, we are screening MCL lines by using a genome-wide siRNA library to identify key components, which are required for aberrant NF-K activation, cell proliferation and survival in MCL cells. This may allow for the development of new treatment approaches for this incurable disease. 2008


©2017 Lymphoma Foundation of America. LymphomoHelp® All rights reserved.
lymphoma foundation of America
lymphoma specialist Kai Fu, MD, phd

Kai Fu, M.D. Ph.D.
___________

Professor of Medicine, University of Nebraska Medical Center

Director of Hematopathology Fellowship

Co-Director, Armitage Center for Hematological Malignancies Research

Director, International Relations Office, Buffett Cancer Center


I am really honored and delighted to receive this award from the Foundation. I appreciate the recognition and support from LFA. I hope my research in pathogenesis and pathobiology of lymphoma will ultimately lead to the cure and prevention of the disease. "I am a physician, teacher, and researcher. My research involves several aspects of the hematopathology of lymphomas. I am working on the pathogenesis of lymphoma with particular attention to the gene expression profiles of B-cell nonhodgkin lymphomas and Burkitts lymphoma. I hope to one day be able to identify genes that predict the biologic behavior of different subtypes of lymphoma.

"The resistance of mantle cell lymphoma to current chemotherapy regimens indicates that new therapeutic approaches are needed. Here at the Nebraska Medical Center, we are screening MCL lines by using a genome-wide siRNA library to identify key components, which are required for aberrant NF-K activation, cell proliferation and survival in MCL cells. This may allow for the development of new treatment approaches for this incurable disease. 2008

©2017 Lymphoma Foundation of America. LymphomoHelp® All rights reserved.
help and support for lymphoma patients and familyHelp for you and
your family
Research for
the cure
Surviving Lymphoma Who we
are
You can help

Kai Fu, M.D. Ph.D.

lymphoma specialist Kai Fu, MD

Professor of Medicine, University of Nebraska Medical Center

Director of Hematopathology Fellowship

Co-Director, Armitage Center for Hematological Malignancies Research

Director, International Relations Office, Buffett Cancer Center


I am really honored and delighted to receive this award from the Foundation. I appreciate the recognition and support from LFA. I hope my research in pathogenesis and pathobiology of lymphoma will ultimately lead to the cure and prevention of the disease. "I am a physician, teacher, and researcher. My research involves several aspects of the hematopathology of lymphomas. I am working on the pathogenesis of lymphoma with particular attention to the gene expression profiles of B-cell nonhodgkin lymphomas and Burkitts lymphoma. I hope to one day be able to identify genes that predict the biologic behavior of different subtypes of lymphoma.

"The resistance of mantle cell lymphoma to current chemotherapy regimens indicates that new therapeutic approaches are needed. Here at the Nebraska Medical Center, we are screening MCL lines by using a genome-wide siRNA library to identify key components, which are required for aberrant NF-K activation, cell proliferation and survival in MCL cells. This may allow for the development of new treatment approaches for this incurable disease.